Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 11, 2026 08:00 ET | Source: Jabez Biosciences, Inc.

Jabez Biosciences Presents First-in-Human Pharmacokinetic and Pharmacodynamic Data for JBZ-001 at AACR Annual Meeting 2026

Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical PBPK Predictions CRANBERRY TOWNSHIP, Pa., May 11, 2026 ...
May 11, 2026 07:55 ET | Source: Clearmind Medicine Inc.

Clearmind Medicine Announces “Inside MEAI” Webinar Featuring New Insights from CMND-100 Psychedelic Clinical Trial

Registration Now Open - Join the Live Webinar on June 10, 2026 Vancouver, Canada, May 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a...
May 10, 2026 05:09 ET | Source: WhiteSwell

WhiteSwell Announces Primary Clinical Trial Results Simultaneously at Heart Failure 2026 Congress and in European Journal of Heart Failure related to the DELTA-HF Study in Acute Decompensated Heart Failure

GALWAY, Ireland, May 10, 2026 (GLOBE NEWSWIRE) -- WhiteSwell, a clinical-stage medtech company pioneering a new treatment paradigm for acute decompensated heart failure (ADHF), today announced...
May 08, 2026 16:05 ET | Source: Longeveron

Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron announced that a constructive Type C meeting with the U.S. FDA was held to discuss the ongoing development of laromestrocel in HLHS.
May 05, 2026 02:00 ET | Source: ALS, Advanced Life Solutions

Organ transplantation: ALS achieved CE Certification for PERLA®, The new class of solution – PPS – and launches a randomized comparative clinical trial (RCT)

Press Release Organ transplantation: ALS achieved CE Certification for PERLA®, The new class of solution – PPS – and launches a randomized comparative clinical trial (RCT) ALS has received CE...
May 05, 2026 02:00 ET | Source: ALS, Advanced Life Solutions

Transplantation d’organes : ALS obtient le marquage CE pour PERLA®, une nouvelle classe de solution - PPS - et lance une étude clinique comparative

COMMUNIQUÉ DE PRESSE Transplantation d’organes : ALS obtient le marquage CE pour PERLA®, une nouvelle classe de solution - PPS - et lance une étude clinique comparative Obtention du marquage CE...
May 05, 2026 02:00 ET | Source: ALS, Advanced Life Solutions

Trasplante de órganos: ALS obtiene el marcado CE para PERLA®, una nueva clase de solución – PPS – desarrollada junto al IDIBAPS (Barcelona), y lanza un estudio clínico comparativo

comunicado de prensa Trasplante de órganos: ALS obtiene el marcado CE para PERLA®, una nueva clase de solución – PPS – desarrollada junto al IDIBAPS (Barcelona), y lanza un estudio clínico...
May 04, 2026 08:00 ET | Source: RENEXXION IRELAND

Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial

Positive P2b trial results on naronapride show significant, meaningful impact on gastroparesis symptoms; with favorable safety and tolerability profiles.
April 30, 2026 11:30 ET | Source: Confo Therapeutics

Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554

Confo Therapeutics announces the Phase 2a clinical trial initiation by Eli Lilly and Company for CFTX-1554 in peripheral pain.
April 29, 2026 07:00 ET | Source: EnteroBiotix

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome

Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBSDosing of first patient of the Phase 2b ‘RISE’...